.png)
Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- Mar 20
- 1 min read
19/03/2026
Remix Therapeutics' REM-422 received the FDA fast track designation for adenoid cystic carcinoma (Ref)
The US FDA granted the fast track designation to Remix Therapeutics' REM-422 (MYB mRNA degrader) for the treatment of patients with recurrent, metastatic or unresectable adenoid cystic carcinoma (ACC) whose tumors express MYB transcripts containing a poison exon.
REM-422 is currently being investigated in the ongoing Phase 1/2 ARIA trial
Peter Smith, Co-Founder and CEO, Remix Therapeutics: “Receiving Fast Track designation for REM-422 underscores the urgent need for new treatment options for patients with ACC. REM-422 represents a novel approach designed to target MYB, a key oncogenic driver in ACC that has historically been difficult to drug. This designation supports our ongoing efforts to expeditiously advance REM-422 through clinical development to bring this potential therapy to patients as quickly as possible.”
Comments